TIDMEVG
RNS Number : 0150V
Evgen Pharma PLC
08 December 2021
Evgen Pharma plc
("Evgen" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that, on 8 December 2021, certain employees
and directors of the Company, including the following Persons
Discharging Managerial Responsibility ("PDMR"), were granted nil
cost options (the "Options") over a total of 4,302,975 ordinary
shares in the Company exercisable, subject to the Options vesting,
for a period of up to 10 years from the date of grant and governed
by the rules of the Evgen Pharma plc Long Term Incentive Plan
("LTIP").
PDMR Position Options granted
Dr Huw Jones Chief Executive Officer 1,670,886
------------------------- ----------------
Richard Moulson Chief Financial Officer 552,911
------------------------- ----------------
Dr Glen Clack Chief Medical Officer 632,911
------------------------- ----------------
Dr Helen Kuhlman Chief Business Officer 708,861
------------------------- ----------------
Vice President, Project
Nick Mallard Leadership 612,089
------------------------- ----------------
The Options will vest on the third anniversary of grant based on
performance against challenging strategic corporate objectives over
three years (40%), share price growth (30%) and on an elapsed time
basis at 3 years (30%).
Following this award there are 9,786,980 options in issue,
representing 3.56% of the Company's issued share capital.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+ 44 (0)7980 541 893 / +44
Paul McManus / Anna Dunphy (0)7876 741 001
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Huw Jones
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Chief Executive
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma Plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of 0.25 pence each
instrument GB00BSWYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 1,670,886
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
-------------------------------------------------------------------------------------- ------------------------
f) Date of the transaction 8 December 2021
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Richard Moulson
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Chief Financial Officer
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of 0.25 pence each
instrument
GB00BSWYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 552,911
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
-------------------------------------------------------------------------------------- ------------------------
f) Date of the transaction 8 December 2021
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Glen Clack
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Chief Business Officer
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of 0.25 pence each
instrument
GB00BSWYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 632,911
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
-------------------------------------------------------------------------------------- ------------------------
f) Date of the transaction 8 December 2021
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Helen Kuhlman
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status Chief Business Officer
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of 0.25 pence each
instrument
GB00BSWYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 708,861
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
-------------------------------------------------------------------------------------- ------------------------
f) Date of the transaction 8 December 2021
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Nick Mallard
----------------------------------------------------------- ---------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------------------------------------
a) Position/status VP Project Management
----------------------------------------------------------- ---------------------------------------------------
b) Initial notification /Amendment Initial Notification
----------------------------------------------------------- ---------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------------------------------------------------------
a) Name Evgen Pharma plc
----------------------------------------------------------- ---------------------------------------------------
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
----------------------------------------------------------- ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Options over ordinary shares of 0.25 pence each
instrument
GB00BSWYN304
Identification code
----------------------------------------------------------- ---------------------------------------------------
b) Nature of the transaction Grant of options
----------------------------------------------------------- ---------------------------------------------------
c) Currency GBP
----------------------------------------------------------- ---------------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------------------------------------- ------------------------- ------------------------
nil 612,089
------------------------------------------------------------------------------------------ ------------------------
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
-------------------------------------------------------------------------------------- ------------------------
f) Date of the transaction 8 December 2021
----------------------------------------------------------- ---------------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
----------------------------------------------------------- ---------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDKFBKQBDDABK
(END) Dow Jones Newswires
December 08, 2021 09:08 ET (14:08 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
